跳到正文
原文
STAT 主站· Elaine Chen·· 24 天前精选AI 评分68

Artiva Biotherapeutics因两例死亡事件关闭自身免疫细胞疗法研发

STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

AI 导读

Artiva Biotherapeutics宣布在两项研究中出现患者死亡后停止运营。其中一例死于神经系统并发症,研究者认为与化疗而非细胞疗法相关;另一例在治后两月突发死亡,原因未定。

推荐理由

两起死亡病例被排除与细胞疗法直接相关,但公司仍决定关停,读者可据此理解该领域安全事件对商业决策的触发逻辑。

正文 · 原文

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Artiva Biotherapeutics said Tuesday that it’s winding down after two patients died in a trial testing its cell therapy for autoimmune diseases, the latest in a series of safety events that emerged in a promising research field.

One participant in the Phase 2 study died from a neurological complication after receiving the treatment, an NK cell therapy. Researchers, however, determined the death was likely not related to the cell therapy itself, but to a chemotherapy that was given before the cell therapy, Artiva said. It’s standard to give patients chemotherapies before infusing cell therapies to lower the patients’ white blood cell count and make room for the new cells.

A second participant experienced sudden death about two months after treatment. Researchers determined that this was not related to any component of the treatment process, but the cause of death has not been determined, the San Diego-based company said.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com